Health and wellness company Perrigo Company plc (NYSE:PRGO)(TASE:PRGO) reported on Wednesday the receipt of the final approval from the US Food and Drug Administration (FDA) for its AB rated Abbreviated New Drug Application referencing Zovirax Cream, 5% (acyclovir cream, 5%) against herpes viruses.
The company added the generic Zovirax Cream, 5% (acyclovir cream, 5%) was developed in collaboration with Sol-Gel Technologies Ltd (NASDAQ:SLGL).
Following the US FDA's approval, the company anticipates launching Zovirax Cream, 5% (acyclovir cream, 5%) this month.
For the 12 months ending December 2018, the annual market sales were approximately USD92m as measured by IQVIA, concluded the company
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval